Cell Village Captures Populational Heterogeneity of Sunitinib Cardiotoxicity.

Sunitinib treatment of iPSC-derived cardiomyocytes from 20 healthy donors shows donor-resolved heterogeneity, with relaxation velocity most consistently linked to cardiotoxicity severity.

• Why it matters: Tyrosine kinase inhibitor cardiotoxicity varies across patients, yet molecular programs and actionable predictors for sunitinib risk are not well defined.
• What they did: The Cell Village platform differentiated pooled iPSCs into cardiomyocytes, exposed them to sunitinib for 72 hours, and used single-nucleus RNA sequencing with SNP demultiplexing; functional phenotyping and tocotrienol recovery were measured in iPSC-CMs from 10 lines.
• The result: Gene modules tied to calcium handling and structural organization correlated with donor-specific toxicity and recovery indices, and tocotrienol produced partial, donor-dependent improvement of sunitinib-related impairments.

AI summary of the abstract · may contain errors · not medical advice · read the paper.